IMNM Immunome, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
00:49
Jan 06
Jan 06
Only speculate, not invest, in Immunome
Cramer warns that Immunome is a clinical-stage biotech losing a lot of money and carrying extreme volatility, so it is only suitable for speculation, not investing.
MED
About IMNM Investor Commentary
Across the available history and selected sources, Buzzberg tracks IMNM (Immunome, Inc.) across 1 sources: 0 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Jim Cramer.